多项减重药研发成果亮相ADA大会，国产药数据比肩跨国同行

Core Insights - The competition in the GLP-1 weight loss drug market is expected to increase as more products enter the market, leading to lower prices and improved accessibility globally [1][3] - Recent clinical data presented at the ADA conference shows that Ecnoglutide, developed by a domestic company, has demonstrated weight loss efficacy comparable to that of Novo Nordisk's Semaglutide [1][3] Group 1: Clinical Data and Efficacy - Ecnoglutide treatment resulted in over 90% of obese and overweight patients losing more than 5% of their body weight, with maximum weight loss reaching 15.4% for the highest dosage [3] - Novo Nordisk's Semaglutide at a higher dosage (7.2mg) showed an average weight reduction of 21%, with one-third of participants losing 25% or more [3][4] - Eli Lilly's oral GLP-1RA, orforglipron, achieved nearly 8% average weight loss at the highest dosage after 40 weeks, alongside a reduction in blood sugar levels [4] Group 2: Market Dynamics and Future Developments - The introduction of more weight loss drugs is anticipated to enhance competition, which is beneficial for market pricing and accessibility [1][3] - Novo Nordisk plans to submit a label update for higher dosage Semaglutide in the EU by late 2025, with subsequent submissions in other markets [4] - Eli Lilly is also advancing the development of an oral version of Semaglutide, which could become the first oral GLP-1 drug to achieve double-digit percentage weight loss if approved by the FDA [4] Group 3: Broader Health Benefits - GLP-1 drugs are being explored for health benefits beyond weight loss, including cardiovascular risk reduction for overweight patients with heart disease [5] - Recent guidelines from the American College of Cardiology recommend prioritizing GLP-1 weight loss drugs for obese patients to lower heart disease risk, contrasting previous recommendations that emphasized lifestyle changes first [5]